Voloridge Investment Management LLC Has $50.91 Million Position in HCA Healthcare, Inc. (NYSE:HCA)

Voloridge Investment Management LLC lowered its position in HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 15.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 169,622 shares of the company's stock after selling 31,553 shares during the quarter. Voloridge Investment Management LLC owned 0.07% of HCA Healthcare worth $50,912,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Norges Bank bought a new stake in HCA Healthcare in the 4th quarter valued at $840,286,000. Royal London Asset Management Ltd. raised its position in HCA Healthcare by 62.0% in the fourth quarter. Royal London Asset Management Ltd. now owns 1,500,786 shares of the company's stock worth $450,461,000 after purchasing an additional 574,239 shares in the last quarter. Barclays PLC grew its stake in shares of HCA Healthcare by 85.7% in the 4th quarter. Barclays PLC now owns 1,061,891 shares of the company's stock valued at $318,727,000 after purchasing an additional 489,916 shares during the period. Principal Financial Group Inc. boosted its stake in HCA Healthcare by 120.1% in the 4th quarter. Principal Financial Group Inc. now owns 873,775 shares of the company's stock valued at $262,264,000 after buying an additional 476,756 shares in the last quarter. Finally, Two Sigma Investments LP raised its stake in HCA Healthcare by 12,016.0% during the fourth quarter. Two Sigma Investments LP now owns 467,437 shares of the company's stock worth $140,301,000 after acquiring an additional 463,579 shares in the last quarter. 62.73% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other HCA Healthcare news, COO Jon M. Foster sold 15,698 shares of the stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $369.32, for a total transaction of $5,797,585.36. Following the completion of the transaction, the chief operating officer now owns 12,646 shares in the company, valued at approximately $4,670,420.72. This represents a 55.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.30% of the stock is owned by company insiders.

HCA Healthcare Stock Down 0.2%

Shares of HCA Healthcare stock opened at $385.95 on Wednesday. HCA Healthcare, Inc. has a 12 month low of $289.98 and a 12 month high of $417.14. The business has a fifty day simple moving average of $343.61 and a 200 day simple moving average of $328.91. The company has a quick ratio of 0.97, a current ratio of 1.08 and a debt-to-equity ratio of 69.07. The stock has a market cap of $92.85 billion, a PE ratio of 17.57, a price-to-earnings-growth ratio of 1.10 and a beta of 1.46.

HCA Healthcare (NYSE:HCA - Get Free Report) last announced its quarterly earnings results on Friday, April 25th. The company reported $6.45 earnings per share for the quarter, beating analysts' consensus estimates of $5.75 by $0.70. HCA Healthcare had a net margin of 8.16% and a return on equity of 586.47%. The business had revenue of $18.32 billion for the quarter, compared to the consensus estimate of $18.26 billion. During the same period last year, the company posted $5.36 EPS. HCA Healthcare's revenue for the quarter was up 5.7% on a year-over-year basis. Research analysts predict that HCA Healthcare, Inc. will post 24.98 EPS for the current year.

HCA Healthcare Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 16th will be issued a $0.72 dividend. The ex-dividend date is Monday, June 16th. This represents a $2.88 annualized dividend and a dividend yield of 0.75%. HCA Healthcare's dividend payout ratio (DPR) is currently 12.81%.

Analysts Set New Price Targets

HCA has been the topic of a number of recent analyst reports. Bank of America reduced their price target on shares of HCA Healthcare from $380.00 to $370.00 and set a "buy" rating on the stock in a research report on Monday, January 27th. Baird R W downgraded HCA Healthcare from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, April 15th. Barclays lowered their target price on HCA Healthcare from $392.00 to $366.00 and set an "overweight" rating for the company in a research note on Monday, January 27th. Robert W. Baird reissued a "neutral" rating and set a $336.00 price objective (down previously from $396.00) on shares of HCA Healthcare in a report on Tuesday, April 15th. Finally, Royal Bank of Canada reduced their target price on shares of HCA Healthcare from $384.00 to $376.00 and set an "outperform" rating on the stock in a research report on Monday, April 28th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $381.13.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.